164 related articles for article (PubMed ID: 27093990)
1. [The significance of serum IgD quantitation for evaluation of clinical efficacy in IgD multiple myeloma].
He J; Zhang H; Jiang H; Zeng T; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):288-91. PubMed ID: 27093990
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
3. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
4. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
[TBL] [Abstract][Full Text] [Related]
5. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
6. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
[TBL] [Abstract][Full Text] [Related]
8. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
9. Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria.
Narita K; Miura D; Tsushima T; Terao T; Kuzume A; Tabata R; Takeuchi M; Matsue K
Sci Rep; 2021 Jul; 11(1):14956. PubMed ID: 34294772
[TBL] [Abstract][Full Text] [Related]
10. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
13. IgD-λ multiple myeloma with excessive excretion of free light chains: a diagnostic trap in the identification of monoclonal gammopathies.
Zahir H; Tali A; Rachidi M; Mouhib H; Daif H; Ait Ouzdi Z; Haouach K; Chabaa L
Ann Biol Clin (Paris); 2019 Feb; 77(1):107-111. PubMed ID: 30799291
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
16. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.
Alejandre ME; Pavlovsky MA; Remaggi G; Corrado C; Fernandez I; Milone G; Pavlovsky A; Madalena L; Pandolfo M; Facio ML; Bresciani P; Pavlovsky S; Pizzolato MA
Clin Chem Lab Med; 2012 Apr; 50(6):1093-7. PubMed ID: 22706252
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
[TBL] [Abstract][Full Text] [Related]
19. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
Dytfeld D; Griffith KA; Friedman J; Lebovic D; Harvey C; Kaminski MS; Jakubowiak AJ
Leuk Lymphoma; 2011 Jul; 52(7):1271-80. PubMed ID: 21699382
[TBL] [Abstract][Full Text] [Related]
20. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
